Purpose: We report pathological, functional and oncologic outcomes in patients treated with radical nephroureterectomy following radical cystectomy. Materials and Methods: We identified patients who underwent radical cystectomy and then radical nephroureterectomy for metachronous urothelial recurrence at our institution between January 1995 and December 2014. Univariable Cox regression was used to assess the association between overall survival and age, grade, stage, lymph node metastasis and radiographic findings. Results: Of the 3,173 patients treated with radical cystectomy 64 underwent subsequent radical nephroureterectomy for metachronous urothelial recurrence. Median age at radical cystectomy was 66 years (IQR 61e74). In the 64 patients who underwent radical nephroureterectomy median time from radical cystectomy to radical nephroureterectomy was 2.7 years (IQR 1.4e4.6). Among 37 patients who underwent ureteroscopy prior to radical nephroureterectomy 29 (78%) had a positive biopsy. Radical nephroureterectomy pathology findings revealed locally advanced disease (pT3/pT4) in 39% of cases and positive node status in 11% compared with locally advanced disease in 17% and positive node status in 6% on radical cystectomy pathology findings. The post-radical nephroureterectomy estimated glomerular filtration rate was less than 60 and less than 30 ml/minute/1.73 m 2 in 96% and 40% of patients, respectively. Median overall survival after radical nephroureterectomy was 3.1 years (95% CI 2.4e4.3). Only lymph node involvement at radical nephroureterectomy was significantly associated with worse overall mortality (HR 2.73, 95% CI 1.04e7.15, p ¼ 0.041). Conclusions: The prognosis is poor in patients with panurothelial carcinoma treated with nephroureterectomy following cystectomy with locally advanced disease in a large proportion. Renal function after these procedures diminished and almost all patients were ineligible for cisplatin based chemotherapy.
UROTHELIAL carcinoma may arise from a panurothelial field defect in the entire epithelial lining of the urinary tract, which is characterized by frequent multifocal metachronous tumors. The biological behavior of and treatment approaches to urothelial tumors are extremely heterogeneous. RC is the gold standard treatment in patients with muscle The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
Supported by David H. Koch funds provided through the Prostate Cancer Foundation, the Sidney Kimmel Center for Prostate and Urologic Cancers, T32 CA082088 (QL, Brett S. Carver) and P30 CA008748 (Craig B. Thompson).
* 1 RNU with excision of the bladder cuff is the gold standard treatment of organ confined disease.
Previous studies included only 16 to 24 patients with upper tract recurrence following radical cystectomy. 2, 3 There is little information regarding clinic management and outcomes in patients with panurothelial carcinoma disease. Metachronous involvement of the upper tract after RC represents a type of aggressive panurothelial disease that may warrant specialized management strategies. We report pathological, renal functional and oncologic outcomes in patients who underwent radical nephroureterectomy to treat metachronous upper tract recurrence following cystectomy at a tertiary referral center.
MATERIALS AND METHODS
After institutional review board approval we retrospectively reviewed prospectively collected data on patients who underwent RC and urinary diversion for UCB at our institution from January 1995 through December 2014. We identified 64 of the 3,173 patients who underwent RC and were also treated with subsequent RNU for metachronous upper tract recurrence for the final analysis. We excluded patients with a prior history of UTUC, concurrent UTUC, concurrent RNU and subsequent RNU for a nonfunctional kidney secondary to ureteral stricture. Demographic, clinical and pathological data were collected by chart review.
After RC patients were generally followed every 3 months in year 1, every 4 months in year 2, every 6 months in years 2 to 5 and annually thereafter. Urine cytology was obtained at each visit. Baseline upper tract imaging was done in most patients after cystectomy followed by annual imaging and imaging performed as clinically indicated to evaluate hematuria, systemic symptoms or abnormal cytology findings. Indications for RNU included endoscopically or pathologically proven recurrence, positive selective cytology and/or abnormal radiographic findings of recurrence in the renal collecting system or ureter. All upper tract recurrences were pathologically confirmed by cytology or endoscopic biopsy (antegrade or retrograde ureteroscopy) or final RNU pathology findings.
We calculated eGFR using the abbreviated MDRD (Modification of Diet in Renal Disease) equation, eGFR ¼ 186 Â (serum creatinine) e1.154 Â (age) e0.203 multiplied by 0.742 for male patients and 1.212 for black patients. 4 Postoperative eGFR was measured close to 6 months (range 3 to 12) after RNU and compared with eGFR before RC and RNU.
OS was determined from the date of RNU until death or the most recent patient contact. Univariable Cox proportional hazards regression was used to test the association between survival and other factors, including RC and RNU grade (low grade vs high grade), RC and RNU stage (pT2 or less vs pT3/pT4), RNU surgical margin, RNU lymph node metastasis, preRC CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) estimated eGFR, pre-RNU CKD-EPI estimated eGFR and various radiographic criteria such as hydronephrosis, filling defects, wall thickening, mass lesions and enlarged lymph nodes. All analyses were done with StataÒ, version 13.
RESULTS
Supplementary table 1 (http://jurology.com/) shows the pathological features of RC and RNU. Median age at RC was 66 years (IQR 61e74). In the 64 patients whom we identified who underwent subsequent RNU the median time from RC to RNU was 2.7 years (IQR 1.4e4.6). RNU pathology findings revealed that 39% of the patients had locally advanced disease (pT3/pT4) while 17% had locally advanced disease at the time of RC. Similarly lymph node metastases and soft tissue margins were more commonly found at RNU than at RC (13% vs 6% and 14% vs 2%, respectively).
Cytology results prior to RNU were positive for malignancy in 37 patients (58%). Of the 37 patients who underwent endoscopy before RNU 29 (78%) had positive biopsies. Among the 31 patients who underwent RNU without a previous positive or suspicious biopsy 1 with a poorly functioning kidney and suspicious ureteral wall thickening had pT0 disease. In the majority of patients with upper tract disease the condition was detected by imaging before RNU. The most common radiographic findings were irregular wall thickening/enhancement in 31 patients (48%), lesions in 24 (38%), hydronephrosis in 18 (28%) and a filling defect in 9 (14%) (see table) . Figure 1 summarizes renal function outcomes. In the 50 patients with complete eGFR measurements the available median eGFR of 55 ml/minute/1.73 m 2 had decreased slightly from the baseline eGFR of 62 ml/minute/1.73 m 2 after RC while median eGFR decreased substantially to 36 ml/minute/1.73 m 2 after RNU. Following RNU 48 patients (96%) had eGFR 60 ml/minute/1.73 m 2 or less and 20 (40%) had eGFR 30 ml/minute/1.73 m 2 or less. Chemotherapy was administered prior to the UTUC diagnosis in 11 patients (17%), including neoadjuvant, adjuvant and salvage chemotherapy for UCB in 6, 3 and 1, respectively, and chemotherapy for other disease in 1. Nine of the 16 patients (56%) treated with neoadjuvant gemcitabine/cisplatin before RNU died and the remaining 7 were alive at a median followup of 2.0 years. While 13 patients received chemotherapy after RNU, none of the regimens (taxol, gemcitabine, carboplatin or clinical trials) was cisplatin based due to poor renal function. Median overall survival in the 13 patients who received chemotherapy after RNU was 3.5 years (95% CI 2.3e5.8) and 12 of the 13 died during followup.
Median followup in survivors in the entire cohort was 2.9 years (IQR 1.6e6.5). The 5-year estimated probability of OS was 32% (95% CI 20e45). Median OS was 3.1 years (95% CI 2.4e4.3, fig. 2 Time from RNU (years) Figure 2 . Probability of overall survival after RNU remnant urothelium. Guidelines refer to surveillance after upper or lower tract extirpative surgeries but do not address the management of panurothelial disease. 5, 6 In this study we observed subsequent worse pathological features in the upper tract compared with pathological features in the bladder in patients treated with RNU following RC. These patients had poor OS and progressively diminished renal function, which rendered almost all of them ineligible for cisplatin based adjuvant chemotherapy after sequential extirpative treatment. We found that lymph node metastasis at RNU was the only prognostic factor associated with overall mortality.
The greatest risk factor for UTUC is a previous history of UCB. A recent meta-analysis of 13,185 patients revealed that the overall prevalence of upper tract recurrence after cystectomy was 0.75% to 6.4% at 2.4 to 164 months. 7 More importantly the meta-analysis demonstrated that upper tract recurrence was more likely to develop in patients with a low grade tumor, concurrent carcinoma in situ, multifocal lesions, superficial cancer, a positive ureteral/urethral margin and negative nodal status based on the cystectomy specimen. Similarly our cohort had relatively favorable pathological features in the RC specimen, including organ confined disease (less than pT2) in 87% of cases and positive node status in 6% compared to large retrospective cystectomy studies with an overall 40% to 45% incidence of extravesical disease (pT3/pT4) and 20% to 25% incidence of positive node status. 8, 9 In contrast, when RNU was performed for metachronous upper tract recurrence, patients demonstrated unfavorable pathological features, including locally advanced disease in 39% and positive node status in 11%.
The disparity between RNU and RC pathology findings may be explained by the fact that patients with unfavorable pathological features in the RC specimen may have died of disease before experiencing metachronous upper tract recurrence. The alternative plausible biological explanation may be related to the accumulated mutations in metachronous UTUC compared with the genetic alterations of UCB at the initial presentation. We found that median time from RC to RNU was 2.7 years and we also observed 20% of late UTUC recurrences 5 years after cystectomy. We are currently investigating the different genetic alterations between UCB and subsequent UTUC in the same patients with late urothelial recurrence. This may further delineate the sequential genetic hits of driver mutations in patients with panurothelial disease.
EAU (European Association of Urology) guidelines state that a previous history of RC is a high risk factor for risk stratification of UTUC and these patients may be considered for extirpative treatment. 5, 10 The poor prognosis in our study suggests that specialized multimodality strategies should be considered, which may improve oncologic outcomes in this highly vulnerable group of patients.
Guidelines have provided surveillance protocols of cytology, imaging studies and urethral wash for UCB following RC. In accordance with surveillance guidelines we found that cytology was positive in 58% of all patients with pathologically confirmed upper tract recurrence. In contrast, all patients had at least 1 abnormal radiographic finding, most commonly wall thickening, enhancement and/or irregularity, followed by lesions and hydronephrosis. Based on physician discretion antegrade or retrograde endoscopic biopsies were performed in 55% of patients and 77% of the biopsies were positive for malignancy. Except for 1 patient, all those who underwent RNU based on radiographic evidence alone were found to harbor urothelial cancer. This is consistent with a recently proposed "empiric evidence-based algorithm" for UTUC in which ureteroscopy can be omitted as part of the diagnostic workup in appropriately selected patients in whom UTUC extirpation is planned based on abnormal radiographic and cytological findings.
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A decline in renal function has been described in patients with UCB and UTUC after radical surgery. A recent study demonstrated decreased renal function during long-term followup in most patients who underwent RC, including a decrease from a baseline median of 62 ml/minute/1.73 m 2 to a median of 55 and 51 ml/minute/1.73 m 2 at 5 and 10 years, respectively. 12 In contrast, median eGFR decreased from 60 to 47 ml/minute/1.73 m 2 after RNU, resulting in only 19% of patients being eligible for chemotherapy. 13 We found that patients had progressively diminished renal function after RC and RNU due to the deteriorating effects of these extirpative surgeries. Renal function in 40% of patients deteriorated to stage 4 chronic kidney disease in our cohort. More importantly when using a cutoff of 60 ml/minute/ 1.73 m 2 , 60% of patients were ineligible for neoadjuvant chemotherapy before RNU and 96% were ineligible for adjuvant chemotherapy after RNU. 6, 13 A recent meta-analysis suggested that cisplatin based chemotherapy for UTUC in the neoadjuvant setting had a promising survival benefit (OS pooled HR 0.43, p ¼ 0.023) compared with survival in those treated with surgery alone.
14 Therefore, neoadjuvant therapeutic strategies should be strongly considered in patients with aggressive features when possible. We are currently enrolling all eligible patients with UTUC who are at high risk in a clinical trial of neoadjuvant chemotherapy with gemcitabine and cisplatin (ClinicalTrials.gov NCT01261728), and another related cooperative group trial is also accruing (ClinicalTrials.gov NCT02412670).
Compromised renal function not only limits therapeutic options but may also contribute to other cause mortality since reduced eGFR has been independently associated with a risk of death and cardiovascular events. 15 However, due to variability in eGFR measurements, statistical modeling constraints and other confounding factors the impact of postoperative eGFR on survival was difficult to assess. Due to the many complexities management of metachronous UTUC after cystectomy should be individualized by multidisciplinary teams who consider multiple factors such as cancer control, the need for dialysis/kidney transplantation and options for further systemic therapy.
It is controversial whether UTUC and UCB have different oncologic outcomes. Rink et al found stage specific different oncologic outcomes between UTUC and UCB following radical surgery 9 but others reported comparable oncologic outcomes. 16 Nevertheless, studies showed that OS from the time of upper tract recurrence after RC was poor and median OS was 0.8 to 4.6 years with most patients dying of metastatic disease. 2, 3, 17 Favaretto et al previously reported the 5-year CSS of 78% in patients with primary UTUC at our institution, excluding patients with previous or concurrent RC. 18 The 5-year probability of OS in our group was 32% (95% CI 20e45), suggesting that panurothelial disease has more aggressive behavior than primary UTUC. In addition, we identified lymph nodal metastasis as a prognostic factor associated with overall mortality, while others found that pathological tumor stage, lymphovascular invasion, tumor architecture and nodal status were independently associated with cancer specific survival in patients with primary UTUC. 18, 19 It should also be noted that the topic of panurothelial disease in patients with metachronous intravesical recurrence after primary RNU was not addressed in our study since it may represent a different natural history and biology, given the disparity of recurrence patterns and oncologic outcomes. Tanaka et al found that 40% of patients experienced intravesical recurrence, including 70% with pTa and 30% with pT1, following RNU for primary UTUC while the rate of bladder progression (muscle invasion or greater) was only 5% after intravesical bacillus Calmette-Gu erin or intravesical chemotherapy. 20 At a median followup of 44 months Kim et al noted a similar finding of intravesical recurrence in 41% and muscle invasive UCB in 6% of 422 patients who underwent RNU for primary UTUC. 21 The first limitation of this retrospective study is the inherent selection and referral bias. Only patients with aggressive disease that warranted RC plus subsequent RNU at a single high volume tertiary cancer center were included. This selection possibly underestimated OS in patients with metachronous upper tract recurrence because those amenable to radical surgery may have significantly better survival than those who are unable to undergo radical surgery.
2,22 Also, our study was limited by the variability of the timing of postoperative serum eGFR measurements. 13 Finally, the lack of other compounding factors, such as a history of smoking and exposure to carcinogens, may overlook the risk of panurothelial tumorigenesis.
Despite these limitations to our knowledge our study represents the largest series of patients with panurothelial disease treated surgically. It includes additional insight into the pathological features and clinical outcomes of this poor risk group.
CONCLUSIONS
Current management of metachronous urothelial recurrence after cystectomy is clinically challenging with limited evidence for informed clinical decision making. We found a poor prognosis in patients with panurothelial disease who were treated with RNU following cystectomy, especially those with nodal involvement. Neoadjuvant therapeutic strategies should be strongly considered in patients at high risk prior to nephroureterectomy when possible, due to the medically compromised state of patients in this setting. Given the variability in disease behavior and the diversity of treatment options, better risk stratification strategies and novel treatment techniques are needed to avoid unnecessary RNU and optimize kidney sparing approaches. In the era of precision medicine emerging biomarkers of risk, therapeutic response prediction, novel topical agents and multimodal therapies could serve to optimize care in these highly vulnerable patients.
